Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Inspire Medical Systems has received a consensus rating of “Hold” from fifteen brokerages, with one rating as a sell, seven as hold, and seven as buy.
• The average 12-month price target set by analysts for Inspire Medical Systems is $148.00, indicating mixed sentiment about the stock's future performance.
• CFO Richard Buchholz recently sold 11,000 shares at an average price of $93.39, resulting in a 19.69% decrease in his position, which has raised some concerns among investors.

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) has been given an average recommendation of "Hold" by the fifteen brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $148.00.

INSP has been the subject of a number of research analyst reports. KeyCorp lowered Inspire Medical Systems from an "overweight" rating to a "sector weight" rating in a research note on Tuesday, August 5th. Evercore ISI decreased their price target on Inspire Medical Systems from $150.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, October 7th. Truist Financial decreased their price target on Inspire Medical Systems from $125.00 to $90.00 and set a "hold" rating for the company in a research note on Wednesday. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $150.00 target price on shares of Inspire Medical Systems in a research report on Friday, October 10th. Finally, Wall Street Zen lowered Inspire Medical Systems from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th.

Insiders Place Their Bets

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of Inspire Medical Systems stock in a transaction on Friday, August 29th. The stock was sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the completion of the sale, the chief financial officer directly owned 44,867 shares of the company's stock, valued at $4,190,129.13. The trade was a 19.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in INSP. Dragoneer Investment Group LLC raised its position in shares of Inspire Medical Systems by 81.4% in the 2nd quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company's stock worth $305,532,000 after acquiring an additional 1,056,808 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Inspire Medical Systems by 214.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,112,925 shares of the company's stock worth $177,267,000 after acquiring an additional 759,090 shares in the last quarter. Frontier Capital Management Co. LLC raised its position in shares of Inspire Medical Systems by 59.9% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 693,203 shares of the company's stock worth $89,957,000 after acquiring an additional 259,716 shares in the last quarter. Man Group plc raised its position in shares of Inspire Medical Systems by 192.9% in the 2nd quarter. Man Group plc now owns 380,298 shares of the company's stock worth $49,351,000 after acquiring an additional 250,456 shares in the last quarter. Finally, Norges Bank purchased a new position in Inspire Medical Systems during the 2nd quarter worth $31,066,000. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $78.92 on Thursday. Inspire Medical Systems has a 52-week low of $70.77 and a 52-week high of $216.01. The firm has a market capitalization of $2.33 billion, a P/E ratio of 45.62, a P/E/G ratio of 2.46 and a beta of 1.16. The stock has a 50 day moving average price of $82.86 and a 200 day moving average price of $120.11.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The firm had revenue of $217.09 million during the quarter, compared to analyst estimates of $214.50 million. During the same period last year, the company earned $0.32 EPS. Inspire Medical Systems's quarterly revenue was up 10.8% compared to the same quarter last year. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, sell-side analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current year.

Inspire Medical Systems announced that its Board of Directors has authorized a share buyback plan on Monday, August 11th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to purchase up to 8.6% of its shares through open market purchases. Shares buyback plans are often an indication that the company's leadership believes its stock is undervalued.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.